Clinical Trials Logo

Crohn Disease clinical trials

View clinical trials related to Crohn Disease.

Filter by:

NCT ID: NCT00374374 Completed - Crohn's Disease Clinical Trials

Treatment With Lactobacillus Rhamnosus and Lactobacillus Acidophilus for Patients With Active Colonic Crohn’s Disease.

Start date: May 2001
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a probiotic containing Lactobacillus Acidophilus and Lactobacillus Rhamnosus is effective as treatment for patients with active colonic Crohn's disease

NCT ID: NCT00364130 Completed - Crohn Disease Clinical Trials

Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial

Start date: February 2007
Phase: N/A
Study type: Interventional

The purpose of this 12-month double blind, placebo controlled randomized trial is to evaluate the effects of daily treatments with low magnitude mechanical stimuli on bone in 160 children with Crohn disease.

NCT ID: NCT00356408 Completed - Crohn's Disease Clinical Trials

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

COSPAR II
Start date: January 2007
Phase: Phase 3
Study type: Interventional

This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).

NCT ID: NCT00348283 Completed - Crohn's Disease Clinical Trials

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.

NCT ID: NCT00343642 Completed - Crohn's Disease Clinical Trials

Dietary Treatment of Crohn's Disease

Start date: September 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.

NCT ID: NCT00338650 Completed - Crohn's Disease Clinical Trials

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

Start date: June 2006
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety

NCT ID: NCT00333788 Completed - Crohn's Disease Clinical Trials

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

Welcome2
Start date: October 2006
Phase: Phase 3
Study type: Interventional

The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581]. It will also assess the effect of subcutaneous CDP870 400 mg on direct cost parameters.

NCT ID: NCT00329550 Completed - Crohn's Disease Clinical Trials

Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active Crohn's disease in the double-blind main study C87037 (NCT00291668).

NCT ID: NCT00329420 Completed - Crohn's Disease Clinical Trials

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical response at Week 6 to induction therapy in the 6-week double-blind main study, C87037 (NCT00291668), but subsequently showed clinical response at Week 14 to repeated induction therapy (dosed at Weeks 8, 10 and 12) in this extension study.

NCT ID: NCT00308581 Completed - Crohn's Disease Clinical Trials

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

Start date: April 2006
Phase: Phase 3
Study type: Interventional

To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab